In:
Diabetes, Obesity and Metabolism, Wiley, Vol. 18, No. 10 ( 2016-10), p. 1045-1049
Abstract:
We investigated the efficacy and safety of empagliflozin over 24 weeks in Asian patients with type 2 diabetes ( T2DM ) using pooled data from four phase III trials. In these trials, patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg or placebo as monotherapy or add‐on to metformin, metformin plus sulphonylurea or pioglitazone ± metformin. In total, 1326 patients from Asia received ≥1 dose of study drug. At week 24, adjusted mean differences versus placebo in change from baseline in glycated haemoglobin ( HbA1c ) were −0.66% [95% confidence interval ( CI ) −0.76, −0.56] and −0.73% (95% CI −0.83, −0.64) and in weight were −1.6 kg (95% CI −1.9, −1.3) and −1.8 kg (95% CI −2.1, −1.5) with empagliflozin 10 and 25 mg, respectively (all p 〈 0.001). Empagliflozin significantly reduced systolic and diastolic blood pressure. The proportion of patients reporting ≥1 adverse event was similar across treatment groups, but events consistent with genital infection were more common in patients treated with empagliflozin 10 mg (3.4%) or 25 mg (2.3%) than placebo (0.9%). Thus in Asian patients with T2DM , empagliflozin reduced HbA1c , weight and blood pressure, and was well tolerated.
Type of Medium:
Online Resource
ISSN:
1462-8902
,
1463-1326
DOI:
10.1111/dom.2016.18.issue-10
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
2004918-3